RBC Capital maintains Doximity at Outperform, raises price target to $34 from $28
RBC Capital kept Doximity at Outperform, increasing its price target to $34 from $28, suggesting a 2.5% upside from the Nov 5 close of $33.18, according to the firm.
How this was made

The 30-second read
Why it matters
The upgrade may attract new buyers and support the stock price in the near term.
Market read
Analyst target raise provides a fresh catalyst for Doximity, offering a modest trading opportunity.
What to watch
Potential headwinds from regulatory scrutiny of digital health platforms.
Background
RBC Capital issued a new price target for Doximity, reflecting optimism on its growth prospects.
Market effects
May lift other health‑tech stocks as analysts reassess sector valuations.
Limited to US markets, primarily affecting Nasdaq health‑tech listings.
Low global impact beyond US investor community.
Counterpoint
Target raise could be premature if recent earnings miss expectations.
Key entities
- AnalystRBC Capital
Equity research firm that issued the price target upgrade.
- CompanyDoximity
US‑listed health‑tech platform (ticker DOX).



